Company

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio
CVDHKG: 6929

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio

OrbusNeich Medical Group Holdings Limited (HKG: 6929), the medical device company, announced the completion of its acquisition of a 100% equity interest in MC Health S.r.l., an Italian distributor —…

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally

Biostar's Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer

Biostar’s Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Junshi Biosciences Reports RMB 2.5 Billion 2025 Revenue – Toripalimab Drives 40% Drug Sales Growth as Losses Narrow
Finanical ReportsHKG: 1877

Junshi Biosciences Reports RMB 2.5 Billion 2025 Revenue – Toripalimab Drives 40% Drug Sales Growth as Losses Narrow

Clinical trial approval / initiationGene therapy

YolTech’s YOLT-202 Wins FDA Phase II/III Approval – In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency

GSK's Arexvy Wins FDA Label Expansion – RSV Vaccine Now Covers High-Risk Adults Aged 18-49
GlaxoSmithKlineGSK

GSK’s Arexvy Wins FDA Label Expansion – RSV Vaccine Now Covers High-Risk Adults Aged 18-49

Biogen's Salanersen Shows 75% NfL Reduction in SMA Phase Ib – Once-Yearly ASO Advances to Phase III
BiogenClinical trial results

Biogen’s Salanersen Shows 75% NfL Reduction in SMA Phase Ib – Once-Yearly ASO Advances to Phase III

Show More